Who Paid My Doc
Kayla Gertsema
Child & Adolescent Psychiatry Kansas City, MO Medical Doctor
NPI 1700176757 CMS profile 924155
10918 Elm Ave Ste 102, Kansas City, MO 64134
General payments
$634
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kayla Gertsema of Kansas City, MO is reported in the CMS Open Payments database as having received $634 across 6 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 70th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $251 | 2 | |
| 2023 | General | $124 | 1 | |
| 2021 | General | $148 | 2 | |
| 2019 | General | $111 | 1 |
Beside peers
- Kayla Gertsema
- Child & Adolescent Psychiatry median
- Middle half of Child & Adolescent Psychiatry
- National median
In program year 2025, general payments to Kayla Gertsema were reported at $251. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.
Show as a table
| Year | Kayla Gertsema | Child & Adolescent Psychiatry median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $111 | $129 | $42–$419 | $163 |
| 2020 | $0 | $81 | $28–$226 | $114 |
| 2021 | $148 | $115 | $31–$326 | $132 |
| 2022 | $0 | $124 | $40–$382 | $149 |
| 2023 | $124 | $130 | $45–$420 | $160 |
| 2024 | $0 | $141 | $42–$490 | $164 |
| 2025 | $251 | $132 | $41–$474 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 4 billing codesPaid by Medicare
$1,352
Medicare patients
11
Services billed
21
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Heart failure | 0% | |
| Osteoporosis | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
6 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Child & Adolescent Psychiatry in Missouri
Ginger Nicol
Child & Adolescent Psychiatry · Saint Louis, MO
Jeffrey Schulman
Child & Adolescent Psychiatry · Saint Louis, MO
Joshua Wilson
Child & Adolescent Psychiatry · Saint Louis, MO
Sobia Shaffie
Child & Adolescent Psychiatry · Independence, MO
Pravesh Deotale
Child & Adolescent Psychiatry · Festus, MO
Michael Kent
Child & Adolescent Psychiatry · Wentzville, MO
Related records
Child & Adolescent Psychiatry in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Child & Adolescent Psychiatry
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.